42 results about "Feeding disability" patented technology

Systems and methods for introducing one or more stimulating drugs and / or applying electrical stimulation to the brain to at least treat or prevent obesity and / or other eating disorders uses at least one system control unit (SCU) producing electrical pulses delivered via electrodes implanted in the brain and / or producing drug infusion pulses, wherein the stimulating drug(s) are delivered to targeted areas in the brain.

A method and apparatus for treatment of an eating disorder includes electrically, mechanically and / or pharmaceutically / chemically stimulating a of the vagus nerve of the lower esophagus, cardia, esophageal / cardia junction, cardia / fundus junction or upper stomach so as to induce afferent action potentials on the vagus nerve. The device may be noninvasively adjusted after implantation to provide increased or decreased restriction on the patient's gastrointestinal tract. Each stimulus may be administered as a series of programmed pulses of defined amplitude, duration and period, to evoke a responsive signal to the brain by the target nerve, effective for producing a temporary feeling of satiety in the person. An implantable stimulus generator may be operatively coupled to a nerve electrode, pressure device or chemical outlet to apply a defined signal to a selected nerve branch. The implantable stimulus generator is programmable to allow clinician programming of defined signal parameters effective to treat the eating disorder of the patient. Methods are also provided to identify electrodes nearest to a branch of the vagus nerve to apply an electrical stimulation signal with improved efficiency.

The present invention involves a method and a system for using electrical stimulation to treat gastrointestinal and / or eating disorders. More particularly, the method comprises surgically implanting an electrical stimulation lead that is in communication with predetermined thoracic vertebral segments to cause spinal nervous tissue stimulation, thus treating a wide variety of gastrointestinal disorders.

Feedback systems and methods communicate implanted sensor-based feedback signals to promote behavior modifications that ameliorate obesity and other eating disorders. The system and methods described may also be applicable to any treatment in which presenting feedback regarding patients' eating and exercise habits is desired. The present invention provides a method and system for treating a patient by collecting ingestion and exercise information about the patient from an implanted sensor and communicating the collected information to the patient, his or her physician and / or other health care providers. In some embodiments, stimulation of the patient's stomach is also provided to reduce caloric intake. In some embodiments, the collected data is transmitted to a central server. Further embodiments may provide access to additional information in conjunction with the collected patient information, such as a calorie database, an exercise planner, and so forth, with the data optionally being used within a social networking system.

New methods for deep brain stimulation (DBS) surgery using two or more electrical leads are provided. The methods are useful for treating a wide variety of brain-associated disorders including movement-related disorders, psychiatric disorders, metabolic / eating disorders, memory disorders, and pain. Methods featuring stimulation of distinct target areas of a subject's brain, such as the thalamic ventralis intermedius (VIM) and the ventralis oralis (VOA / VOP) using multiple electrical leads for treatment of tremor provide superior clinical outcomes to stimulation with single leads implanted in these target areas.

Methods and systems for treating patients suffering from eating disorders, e.g. obesity, through the dispensation of a drug by an implantable infusion pump (IIP) delivering drug into the cerebral spinal fluid (CSF) at a site of the intrathecal space in amounts and at times effective to suppress the patient's appetite through interaction of the drug transported through the CSF with receptors in the brain. Delivery of a programmed drug dosage is preferably by one of time-out of programmed time(s) of day, a command received from the patient, or a trigger signal developed from a sensed GI tract signal accompanying peristalsis.

Systems and methods are provided for modulating the autonomic nervous system by the electrical stimulation of the neuro-muscular system of a patient, and include an implantable electrical system for gastrointestinal stimulation which incorporates a heart rate sensor to indicate the neurovegetative patient condition, to initiate and terminate stimulation at specific locations, and an algorithm to automatically control electrical stimulation frequency, interval, amplitude, or a combination of such parameters for adaptive treatment of obesity, anorexia, other eating disorders, diseases related with the so called “metabolic syndrome” (e.g., impaired glucose tolerance and diabetes type 2, GERD, systemic hypertension, early arterovascular degeneration, early senility, and the like), and disorders related to a pathologic imbalance of the autonomic nervous system.

Methods and systems of treating a patient having an eating disorder involving coupling at least one electrode to at least one cranial nerve of the patient, implanting a sensory stimulation device in the patient, applying a sensory stimulus to the patient using the sensory stimulation device, detecting the patient's response to the sensory stimulus, and applying an electrical signal to the cranial nerve using the electrode after detecting the response to treat the eating disorder. The methods and systems are effective in treating bulimia.

The present invention is concerned with compounds of the general Formula I: and pharmaceutically acceptable salts thereof, which are useful as melanin concentrating hormone receptor antagonists, particularly MCH-1R antagonists. As such, compounds of the present invention are useful for the treatment or prevention of obesity or eating disorders associated with excessive food intake and complications thereof, osteoarthritis, certain cancers, AIDS wasting, cachexia, frailty (particularly in elderly), mental disorders stress, cognitive disorders, sexual function, reproductive function, kidney function, locomotor disorders, attention deficit disorder (ADD), substance abuse disorders and dyskinesias, Huntington's disease, epilepsy, memory function, and spinal muscular atrophy. Compounds of formula I may therefore be used in the treatment of these conditions, and in the manufacture of a medicament useful in treating these conditions. Pharmaceutical formulations comprising one of the compounds of formula (I) as an active ingredient are disclosed, as are processes for preparing these compounds.

A method and apparatus for treatment of an eating disorder includes electrically, mechanically and / or pharmaceutically / chemically stimulating a of the vagus nerve of the lower esophagus, cardia, esophageal / cardia junction, cardia / fundus junction or upper stomach so as to induce afferent action potentials on the vagus nerve. The device may be noninvasively adjusted after implantation to provide increased or decreased restriction on the patient's gastrointestinal tract. Each stimulus may be administered as a series of programmed pulses of defined amplitude, duration and period, to evoke a responsive signal to the brain by the target nerve, effective for producing a temporary feeling of satiety in the person. An implantable stimulus generator may be operatively coupled to a nerve electrode, pressure device or chemical outlet to apply a defined signal to a selected nerve branch. The implantable stimulus generator is programmable to allow clinician programming of defined signal parameters effective to treat the eating disorder of the patient. Methods are also provided to identify electrodes nearest to a branch of the vagus nerve to apply an electrical stimulation signal with improved efficiency.

A method and apparatus for treating persons suffering from an eating disorder includes direct or indirect stimulation of selected areas of the brain associated with a symptom of the eating disorder. The stimulation regimen is programmable to enable physician optimization of stimulation signal parameters to ameliorate at least one symptom of bulimia or another eating disorder. Certain embodiments employ deep brain stimulation and / or sensing together with cranial nerve stimulation and / or sensing.

The present invention involves a method and a system for using electrical stimulation to treat gastrointestinal and / or eating disorders. More particularly, the method comprises surgically implanting an electrical stimulation lead that is in communication with predetermined thoracic vertebral segments to cause spinal nervous tissue stimulation, thus treating a wide variety of gastrointestinal disorders.

A stimulator device for providing stimulation to the gastrointestinal tract of a user including a housing, at least two electrodes, and a pulse generator. The housing has an exterior surface and an interior surface defining a sealed interior space. The housing is constructed of bio-compatible materials and sized and shaped for transport through the gastrointestinal tract. A portion of the at least two electrodes is disposed on the exterior surface of the housing. The pulse generator is disposed in the interior space of the housing and delivers pulses to the electrodes. Also presented are methods of using a stimulator device in the treatment of: gastrointestinal disorders such as dysphagia, gastroesophageal reflux diseases, functional dyspepsia, gastroparesis, postoperative ileus, irritable bowel syndrome, constipation, diarrhea, fecal incontinence, nausea and vomiting; gastrointestinal obstruction or pseudo-obstruction; pain and / or discomfort related to visceral organs; eating disorders, such as obesity, binge eating, bulimia, anorexia, and chemotherapy-induced emesis or emesis of other origin.

A method for treating eating disorders by repeatedly administering naloxone in a dosage sufficient to block the effects of opiate agonists to a subject suffering from an eating disorder caused by one or more related problem responses; while the amount of naloxone in the subject's body is sufficient to block opiate effects, having the subject make one of the problem responses from which the subject suffers in the presence of stimuli similar to those to which it had been learned, after the amount of naloxone is no longer sufficient to block opiate effects, having the subject make healthy eating responses to food items that do not trigger the problem responses; and continuing the steps of administration of naloxone and having one after another of the problem responses made, followed by having a naloxone-free period in which healthy eating occurs, until the problem responses are extinguished.

Methods of treating psychiatric disorders are provided which include administration of one or more anti-epileptic agents and, optionally, one or more a psychostimulants. Also provided are pharmaceutical compositions comprising, in combination, one or more anti-epileptic agents and one or more psychostimulants. Psychiatric disorders include those associated with impaired cognitive processing, degenerative disorders such as Mild Cognitive Impairment, Parkinson's disease, dementia, non-compliance with therapeutic regimes and eating disorders, although without limitation thereto.